Health ❯ Healthcare ❯ Immunotherapy

Cancer Treatment

Clinical Trials PD-1 Inhibitors Research Innovations Durvalumab Targeted Therapies Immune System Interaction Intratumoral Interactions Vaccine Development Patient-Specific Approaches Targeted Therapy Antibody Development Bowel Cancer Vaccines Macrophages Tissue-Resident Memory T Cells Non-Hodgkin Lymphoma Patient Experience Anktiva Bladder Cancer ANKTIVA® Bifunctional Superkines Rare Diseases Keytruda Dendritic Cell Vaccines Anti-PD-1 Therapy Radiation Therapy

Thymus Radiation Linked to Worse Survival in Lung Cancer Patients

AI analysis of routine chest CTs found dose-related damage to the immune organ that may raise the risk of distant metastasis and has prompted calls for trials of organ-sparing radiotherapy.

PROTEXI Vaccine Redirects COVID‑19 Immune Memory to Target Tumors

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Study Pinpoints GPR25 as Switch for Tissue-Resident Memory T Cell Formation

Antibody Blocking SLAMF6 Restores T-Cell Attack on AML in Preclinical Study

AI Drives Next-Generation Melanoma Immunotherapies Toward In Vivo Testing